$34.47
-0.86-2.43%
最終更新: Oct 23, 4:00 PM
Benzinga
Benzinga
Benzinga
日曜日, 10 25
Benzinga
© 2026 Benzinga | All Rights Reserved
Indivior Pharmaceuticals (INDV) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Indivior Pharmaceuticals (INDV) は、8 3, 2026日にfiscal yearの2026に関するガイダンスを直近で発表しました。同社は当期の売上高を$1.29B - $1.36Bの範囲と予想しています。
以前のガイダンスと比較して、Indivior Pharmaceuticalsは売上高予測を以前の範囲である引き上げから$1.22B - $1.28Bに引き上げました。
Indivior Pharmaceuticalsは、17から10 23, 2023の間に8 3, 2026ガイダンスの更新を発表しました。During this period, the company raised its outlook 5 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.92 | $0.66 | $0.66 | $0.40 |
| Actual | $1.15 | $0.96 | $0.82 | $0.72 |
| Surprise | +25.0% | +45.5% | +24.2% | +80.0% |
| Revenue | ||||
| Estimate | $306.8M | $272.0M | $305.5M | $261.1M |
| Actual | $343.0M | $317.0M | $358.0M | $314.0M |
| Surprise | +11.8% | +16.5% | +17.2% | +20.3% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $1.08 | $1.19 | $1.00 |
| Revenue | |||
| Consensus | $328.8M | $336.6M | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $1.15 | $0.92 | 25.0 % |
| Q1 | Apr 30, 2026 | $0.96 | $0.66 | 45.5 % |
| Q4 | Feb 26, 2026 | $0.82 | $0.66 | 24.2 % |
| Q3 | Oct 30, 2025 | $0.72 | $0.40 | 80.0 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Aug 3, 2026 | $343.00M | $306.84M | 11.8 % |
| Q1 | Apr 30, 2026 | $317.00M | $272.00M | 16.5 % |
| Q4 | Feb 26, 2026 | $358.00M | $305.46M | 17.2 % |
| Q3 | Oct 30, 2025 | $314.00M | $261.12M | 20.3 % |